Home / Tag Archives: tildrakizumab

Tag Archives: tildrakizumab

IL-23 Blocker for Psoriasis Successful in Extension Trials


GENEVA — Tildrakizumab, an investigational interleukin (IL)-23p19 inhibitor, appears to be effective for the treatment of chronic plaque psoriasis, according to long-term extensions of two phase 3 trials: reSURFACE1 and reSURFACE2 (Lancet. 2017;390:276-288). More than 80% of patients treated with tildrakizumab 200 mg for 2 years achieved a 75% reduction in Psoriasis Area Severity Index …

Read More »